Inglise keel​​​​​​​ Eesti keel

Menu

Close

Resources
Interactions Finder
PAXLOVID®  (nirmatrelvir; ritonavir) is authorised in Estonia, nirmatrelvir is also known as PF-07321332

Marketing Authorisation has been granted in the EU for PAXLOVID® for the treatment of coronavirus disease 2019 (COVID-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.

Summary of Product Characteristics (SmPC)  Package Leaflet: Information for the Patient Ensuring the Authenticity  Interactions Finder Report an Adverse Event
Blue Box InformationEstonia
Prescription drug.
Shelf-life Extension

On 15 February 2023, a new shelf life of 24 months (instead of the previous 18 months) was approved for PAXLOVID in the European Union.

PAXLOVID Summary of Product Characteristics (SmPC) 

View the full Summary of Product Characteristics, which includes dosing, clinical data, and safety information. 

Click here
PAXLOVID Package Leaflet: Information for the Patient

View the Package Leaflet, which contains important information for the patient about how to take PAXLOVID® and what to expect from treatment.

Click here
Ensuring the Authenticity of PAXLOVID

Authentic PAXLOVID® from Pfizer will include the Pfizer name on the outer carton and will be packaged in 5 aluminium push-through blister cards. To ensure that the tablets are legitimate, look for specific text debossed on each side of the tablets. Nirmatrelvir tablets are pink, oval-shaped and debossed with ‘PFE’ on one side and ‘3CL’ on the other side.​ Ritonavir tablets are white to off white, capsule shaped, and debossed with ‘H’ on one side and ‘R9’ on the other side.  

The outer carton has a colourless, glossy coating that contains a repeated pattern of the Pfizer name and logo all over. The Pfizer name and logo appear in a contrasting matte finish. 

The flaps at each end of the carton are glued as a tamper evident feature of the packaging.

If you suspect the PAXLOVID® you have received may be counterfeit, please report it to your local representative via  +372 666 7500.

Next PageInteractions Finder

This site is intended only for the Republic of Estonia healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

Copyright © 2023 Pfizer Inc. All rights reserved. PP-C1D-EST-0001

Eesti tervishoiutöötajatele

Need lehed ei ole mõeldud patsientidele ega laiemale avalikkusele.

Kinnitan, et olen Eestis resideeruv tervishoiutöötaja.

Kui valite „Ei“, suunatakse teid lehele covid19oralrx.com, kus saate juurdepääsu PAXLOVID® (nirmatrelviir; ritonaviir) kohta käivale lisateabele. Nirmatrelviir tuntakse ka kui PF-07321332

    Jah        Ei